Abstract
Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Current Cancer Therapy Reviews
Title: NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Volume: 4 Issue: 2
Author(s): Renu Datta, Catherine L. Riley, Italo A. Dodi and Robert C. Rees
Affiliation:
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Abstract: Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Export Options
About this article
Cite this article as:
Datta Renu, Riley L. Catherine, Dodi A. Italo and Rees C. Robert, NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310133
DOI https://dx.doi.org/10.2174/157339408784310133 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Recent Progress: Gynecologic Oncology Group Trials in Uterine Corpus Tumors
Reviews on Recent Clinical Trials Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design MiRNA, a New Treatment Strategy for Pulmonary Fibrosis
Current Drug Targets Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry FOXO1: A Potential Target for Human Diseases
Current Drug Targets Translating Mismatch Repair Mechanism into Cancer Care
Current Drug Targets Synthesis, Cytotoxicity Evaluation and Molecular Docking of Fluorine Containing Hexahydroquinoline-3-Carbonitrile Derivatives
Current Drug Discovery Technologies Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder
Current Psychopharmacology Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry